<DOC>
	<DOCNO>NCT00422825</DOCNO>
	<brief_summary>This single center , four-treatment , four period , crossover study evaluate effect food relative bioavailability single dose imatinib ( STI571 ) give 800 mg modify release tablet , MR2 compare twice-daily dos 400 mg film-coated imatinib tablet . There 10 day wash phase treatment 1 week safety period end study . Each participant receive four treatment</brief_summary>
	<brief_title>Effect Food Bioavailability Modified Release Formulation Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion Healthy male female subject ( postmenopausal woman ) Able communicate well investigator comply requirement study . Exclusion criteria Smokers Subjects use prescription drug overthecounter ( OTC ) medication ( include herbal alternative medication ) within 2 week prior dose . Participation clinical investigation within 4 week prior dose longer required local regulation . A past medical history presence clinically significant ECG abnormality include : History acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) . History medication predispose subject GI bleedings/cerebral hemorrhage . Women take biphosphonates ( Fosomax like drug ) History immunocompromised , include positive HIV test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Females nurse infant . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Food effect</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>imatinib</keyword>
	<keyword>STI571</keyword>
	<keyword>modify release formulation STI571</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Philadelphia Chromosome</keyword>
</DOC>